| Oscar Insurance Guidelines | Restasis cyclosporine ophthalmic emulsion 0.05- | 2025-12-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: Direct Acting Antiviral Agents for Hepatitis C | 2025-12-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: azelaic acid 15% gel | 2025-12-01 |
| UHC Medicare Advantage | Orthopedic Procedures, Devices, and Products - Medicare Advantage Medical Policy | 2025-12-01 |
| UHC Medicare Advantage | Prostate Services and Procedures and Impotence Treatment - Medicare Advantage Medical Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Benlysta® (Belimumab) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Evenity® (Romosozumab-Aqqg) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Ophthalmologic Complement Inhibitors - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Rebyota® (Fecal Microbiota, Live-Jslm) - Commercial Medical Benefit Drug Policy | 2025-12-01 |
| UHC Commercial Medical & Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) - Commercial Medical Benefit Drug Policy | 2025-12-01 |